Tuesday, January 19, 2021


Emerging Growth Companies NASDAQ

As the U.S administers millions of vaccines nationwide virus mutations could...

Avalon GloboCare is in the process of establishing a state-of-the-art research facility, the Christian Doppler Laboratory, located on the BOKU campus in Vienna, Austria, under the scientific leadership of Professor Eva-Kathrin Ehmoser, the Head of BOKU’s Institute for Synthetic Bioarchitectures and Professor Uwe Sleytr, a member of the Austrian Academy of Sciences.

Stocks involved in Covid-19 Testing could be the all out Winners

Another solid player in the COVID-19 test kit market is Avalon GloboCare (NASDAQ: AVCO) who recently partnered with Adial Pharmaceuticals (NASDAQ: ADIL) announcing a Strategic Collaboration for Global Distribution of COVID-19 Point-of-Care Antibody Rapid Test Devices

This Stock is Confident Vaccine is Effective against Variants in UK,...

As the war against COVID-19 wages on there are a large number of Bio-Tech players racing to get an effective vaccine to market and with the new South African strand there is a concern with who’s will be effective. Another company to keep your eye on is Avalon GloboCare (NASDAQ: AVCO) who are using a proprietary S-Layer “surface layer” technology to develop an intranasal vaccine that attaches to the mucosal membrane CEO Dr. David Jin pointed out.

COVID-19 Winners in a Post Pandemic World

With the potential of a ‘twindemic’ of influenza and SARS-CoV-2 during fall and winter, Avalon GloboCare (NASDAQ: AVCO) is also planning to conjugate the S-layer matrix with an antigenic signature from both SARS-CoV-2 and the influenza virus for one spray that, if proven effective, would provide protective immunity against both viruses. Novarex trades 100X higher price then Avalon and needs the vaccine to be administered twice as opposed to once.

Cramer Adds New Stocks to his COVID-19 Index

Avalon GloboCare Corp. (NASDAQ: AVCO) a leader in cell-based technology, is launching two major clinical trials to test its blood filtration technology to combat ‘cytokine storms’ induced in some COVID-19 patients and nasal spray vaccine to prevent COVID-19.

CytoDyn Update Reveals Q1 Sales Pipeline, Philippine EUA, NASDAQ Uplisting, &...

CytoDyn Inc. (OTCMKTS: CYDY) may have given one of its last updates as an OTC company yesterday and revealed a number of positive surprises. They could be saying hello NASDAQ, and hello EUA in the course of the next couple of weeks.

BuyersStrike Short Attack Ahead of NASDAQ Uplisting

This morning shares of CytoDyn Inc. (OTMKTS: CYDY) screamed higher in very active trading and touched $7.00 per share to a $4.14 billion market...

Rapid Countermeasure Against COVID-19: Therapeutics Not Vaccines

In the interim, no patients can get the drug via emergency IND because the FDA has stopped that access. This is a point of moral outrage. By not looking at the interim data for leronlimab in an urgent fashion the FDA is condemning thousands of people to death daily.

Genetron (NASDAQ: GTH) Stock Rises 9% on Soaring Sales

China’s leader in early cancer screening said in a statement today that its revenue in the three months through September reached $16.5 million, a 38% increase year-over-year.

Weebit Nano Ltd (ASX:WBT) Moving forward on multiple fronts

WBT has successfully continued its development progress on multiple fronts, such as R&D and pre-production, despite the setbacks of COVID-19. This reaffirms our confidence in management’s ability and the technology’s potential. We continue to expect strong upside potential for this stock and reiterate our intermediate valuation of A$1.36 per share.